Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Yahoo! Finance
This approval ends a four decade gap in motion sickness treatments. See our latest analysis for Vanda Pharmaceuticals. That FDA approval comes after a sharp run, with a 30 day share price return of 53.06% and a 90 day share price return of 55.22%. The 1 year total shareholder return sits at 72.23%, suggesting momentum has strengthened recently despite a 1 day share price pullback of 6.46% to $8.25. If this kind of biotech catalyst has your attention, it could be a good time to look across healthcare stocks for other potential ideas in the sector. So with VNDA trading at US$8.25, sitting on a deep modelled intrinsic discount and a sizeable gap to analyst targets, is the market underestimating the NEREUS opportunity or already pricing in a substantial amount of future growth? With Vanda Pharmaceuticals last closing at US$8.25 and the most followed narrative pointing to fair value closer to US$12.67, the gap hinges on some punchy growth expectations and margin shifts over the c
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag DisorderPR Newswire
- Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=VNDA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
VNDA
Earnings
- 10/29/25 - Miss
VNDA
Sec Filings
- 1/9/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 12/31/25 - Form 8-K
- VNDA's page on the SEC website